
Fulltext:
48318.pdf
Embargo:
until further notice
Size:
81.35Kb
Format:
PDF
Description:
publisher's version
Publication year
2005Source
Nederlands Tijdschrift voor Geneeskunde, 149, 17, (2005), pp. 912-916ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Cardiology
Journal title
Nederlands Tijdschrift voor Geneeskunde
Volume
vol. 149
Issue
iss. 17
Page start
p. 912
Page end
p. 916
Subject
NCEBP 14: Cardiovascular diseases; UMCN 2.1: Heart, lung and circulationAbstract
Antithrombotic therapy is essential during percutaneous coronary interventions for the prevention of peri-procedural death and myocardial infarction. The most commonly used agents are aspirin, clopidogrel and heparin in patients treated by percutaneous angioplasty or receiving an arterial stent. Glycoprotein IIb/IIIa receptor antagonists such as abciximab are indicated during percutaneous interventions in high-risk-patients as well as, in principle, in all patients with an acute coronary syndrome with ST-segment elevation undergoing primary percutaneous angioplasty. In patients with so-called drug-eluting stents, clopidogrel should be continued for several months longer than the usual 30 days.
This item appears in the following Collection(s)
- Academic publications [203856]
- Electronic publications [102283]
- Faculty of Medical Sciences [80326]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.